Immunotherapy in China

Five unrelated families of treatment are sold under one word, and China’s rules treat them very differently. Some immunotherapies have full national marketing approval and are given in ordinary Chinese hospitals. One family — adoptive immune cell therapy — was sold commercially, was stopped after a public scandal in 2016, and returned under a licence that attaches to a named disease and never to age. Here is which is which, and where NK cell therapy actually sits.

The short answer

“Immunotherapy” is not one treatment. It is a word covering at least five families that share only a strategy — getting the patient’s own immune system to do the work — and nothing else. Checkpoint inhibitors are small-volume drug infusions given in any oncology day unit. CAR-T is a manufactured living product costing as much as a house. Cytokines are decades old. Cancer vaccines are mostly still in trials. And adoptive cell therapy — taking immune cells out, growing them, putting them back — is the family that includes NK cells, CIK cells and the tumor-infiltrating lymphocytes, and it is the family with the most complicated legal history in China.

In mainland China the split runs cleanly along that seam. Checkpoint inhibitors and several CAR-T products have national marketing approval from the drug regulator and are prescribed like any other cancer medicine. Adoptive immune cell therapies other than the approved CAR-T products have no marketing approval; they run inside clinical research, or inside a special pathway such as the Boao Lecheng pilot zone, under State Council Order No. 818, in force since 1 May 2026, which licenses a cell therapy against a named disease and never against ageing.

That second sentence is the one that disappoints most people who write to us. There is a real and growing science of immune ageing, and there is no licensed immunotherapy for it — here or anywhere. What follows is the map: the five families, what China has actually approved, why the 2016 rules look the way they do, where the NK program at Boao Lecheng sits inside all of it, and what the immune-ageing research does and does not yet support.

Five families wearing one word

Two of these families matter for anyone reading this from outside China. Checkpoint inhibitors matter because most people who ask us about immunotherapy have already had them, or are on them, and want to know what comes next. Adoptive cell therapy matters because it is the family that gets advertised to medical travellers — and the only one where the gap between what is advertised and what is licensed is wide enough to walk through.

What China has actually approved

It is worth being precise, because “immunotherapy in China” is written about as though the country were one undifferentiated market. It is not.

Checkpoint inhibitors. China’s regulator approved the first domestically developed PD-1 antibodies in 2018, and the class has expanded fast since, across lung, liver, oesophageal, gastric, nasopharyngeal and other cancers. These are ordinary prescription medicines. They are given in hospital oncology departments across the country, they are on the national reimbursement list for many indications, and nothing about them is exotic or zone-specific. If you are already on a checkpoint inhibitor at home, you are on the same class of drug a Chinese oncologist would reach for.

CAR-T. Since 2021 several chimeric antigen receptor T-cell products have won full national marketing approval in China, for relapsed or refractory B-cell lymphoma and, later, multiple myeloma. These are manufactured from the patient’s own T cells at licensed facilities, delivered in accredited hospitals with intensive-care capability, and priced accordingly. CAR-T is real, approved, and has nothing to do with wellness travel: it is a treatment of last resort for specific blood cancers, requiring an in-country haematology team and a bed.

Everything else. NK cells, CIK and DC-CIK, TILs, most TCR-T — none of these has a marketing approval in China as a finished product. That does not make them unavailable; it makes the route they travel on the thing you have to ask about. In practice there are two lawful routes: a registered clinical trial or investigator-initiated study, and a special pathway such as the Hainan pilot zone, where a hospital holds a filing for a specific cell product against a specific set of indications. The Boao Lecheng zone is the second kind.

Why the rules look the way they do: 2016

You cannot understand immune cell therapy in China without the 2016 case, and almost nothing written for foreign patients mentions it.

Between 2009 and 2015, autologous immune cell therapy sat on a national catalogue of restricted “third-class” medical technologies — permitted in approved hospitals, under an approval regime. In 2015 that third-class technology approval system was abolished as part of a wider deregulation, and responsibility devolved. The practical effect was a gap: a treatment that had been sold under an approval regime was suddenly being sold without one, as a paid clinical service, by hospitals and by departments leased to outside operators.

In April 2016 a 21-year-old student named Wei Zexi died of synovial sarcoma after paying for DC-CIK therapy at a Beijing hospital department he had found through a search engine advertisement, having been told the treatment was a foreign collaboration with high success rates. It was not. The case became a national scandal, took in the search engine’s advertising practices and the leasing of hospital departments to private operators, and produced a fast regulatory response: the health authority ordered that autologous immune cell therapy be treated as clinical research, not as a saleable clinical service.

Almost the entire shape of Chinese cell-therapy regulation since then — the research-only default, the insistence on a named disease indication, the hospital-held filing, the mandatory outcome reporting inside the pilot zone, and in due course the framework Order 818 put in place in 2026 — is downstream of that case. When a Chinese hospital tells you a cell therapy is licensed only against a diagnosis, it is not being obstructive. It is applying a rule written in response to somebody dying of the alternative.

The same history explains why DC-CIK, the therapy China was once most associated with internationally, is not something we point people toward. The published evidence is genuinely mixed — a long series of mostly small, single-centre, unblinded Chinese trials and the meta-analyses built on them, reporting modest progression-free and overall survival signals in several cancers, and no regulator anywhere has been persuaded to approve it. That is not the same as saying it does nothing. It is saying that after two decades the evidence still has not settled, and a treatment whose evidence has not settled is a trial question, not a purchase.

Where NK cell therapy sits

Natural killer cells are the innate immune system’s first responders: they kill abnormal cells without having to be taught a specific target first, which is exactly the property that makes them interesting after cancer treatment and exactly the property that makes them hard to aim. The partner hospital in the zone holds a filing for autologous NK cell therapy — your own cells, drawn, expanded in a licensed GMP cleanroom against release criteria, and reinfused — as disease treatment, for adults after resection or checkpoint-inhibitor therapy across a defined set of solid tumors, and for immune rebuild after chemotherapy or radiation. The NK guide on this site sets out the filed indications, the exclusion criteria, the three-infusion course and the trial evidence in full, and the country comparison covers how Japan, Vietnam and Thailand each license the same idea differently.

Three things follow from that, and they are the three things people most often get wrong.

It is not a general immune boost. The filing names diseases. A healthy 52-year-old who would like more NK cells because a clinic in another country offers exactly that is not a candidate here, and no amount of asking changes it. If the assessment finds something, or you arrive holding a diagnosis and a prescription from your own physician, the disease pathway opens — that is the whole of the rule, and it is not a negotiating position.

It is adjunct, not replacement. Nothing in the zone displaces surgery, chemotherapy, radiation or your own oncologist’s plan, and no hospital there may promise an outcome.

The honest evidence claim is narrow. What the NK trial literature supports well is feasibility and tolerability: the cells can be expanded and given, and they are generally well tolerated. What it does not yet support is efficacy in solid tumors, where getting enough cells into the tumor and keeping them alive and functional once there remains the recognised obstacle. Anyone who tells you otherwise is ahead of the data.

Immune ageing, which is the question most people are really asking

Strip the vocabulary away and a large share of the letters we get are not about cancer at all. They are a version of: my immune system is not what it was, can something be done? That is a real phenomenon with a real literature, and it deserves a straight answer rather than a brochure.

What changes with age is better described as remodelling than as simple decline. The thymus — the organ that trains new T cells — begins shrinking in adolescence and is largely replaced by fat by middle age, so the supply of naïve T cells able to respond to a genuinely new threat falls steadily. The repertoire that remains skews toward memory and effector cells shaped by a lifetime of past infections, with large clonal expansions in people carrying cytomegalovirus. Low-grade systemic inflammation rises with age — the phenomenon Claudio Franceschi named inflammaging in 2000 — and it is associated with frailty and with most of the major age-related diseases. NK cell numbers in blood often rise with age while cytotoxic function per cell falls, which is why a raw count is a poor readout.

The clinical consequences are not subtle: worse responses to vaccination, more severe outcomes from respiratory infection, and reduced immune surveillance at exactly the age when cancer incidence climbs. Vaccine response is the most useful functional readout available in ordinary practice, which is why high-dose and adjuvanted influenza formulations exist for older adults at all.

So can it be reversed? The honest state of play is that one small trial is doing most of the work in the popular coverage. In 2019 Gregory Fahy and colleagues published TRIIM, a one-year study in Aging Cell of nine healthy men, given growth hormone with DHEA and metformin, reporting regeneration of thymic tissue on imaging in seven of them and a mean epigenetic age about 2.5 years lower than baseline. Nine men, no control group, an unblinded design, a surrogate endpoint, and a hormone with a known adverse-effect profile. It is a genuinely interesting result and it is a pilot. It is not a treatment, it is not licensed anywhere as one, and a clinic quoting it at you as a reason to buy something today has told you more about itself than about the science. The larger follow-up work exists precisely because the first study cannot bear the weight.

What does have evidence behind it for immune ageing is duller and available everywhere: keeping vaccinations current with the age-appropriate formulations, maintaining muscle mass and cardiorespiratory fitness, treating the chronic conditions that drive inflammation, sleep, and not smoking. A screening battery can tell you where you stand — inflammatory markers, lymphocyte subsets, vaccine-relevant serology, and the metabolic drivers underneath them. Measurement, a correct baseline and a plan is a defensible thing to sell. An anti-ageing immune infusion is not, and under Order 818 it is not lawful here regardless. That is the same line the anti-aging treatment guide draws across the whole shelf.

What this means for a trip

The order of operations here runs one way, and it is the opposite of how most cell-therapy tourism is sold. You do not choose a treatment and then come. You come, you are measured, a specialist panel reads what came back, and only then does anyone discuss whether a licensed program applies to you. The four days are a screening battery, a panel and a written plan — from about $2,700 all in, against published Alpine longevity programmes at roughly $39,000 to $115,000 for a week. If the assessment or your existing records establish a qualifying diagnosis, the treating hospital’s specialists decide candidacy for a licensed program against its filed criteria, and what that costs is quoted by the hospital in writing, never from a menu.

If you already hold a cancer diagnosis and are considering coming for immunotherapy specifically, the useful preparation is documentary: pathology report, staging, treatment history, current medications, recent imaging, and a clear statement from your own oncologist of what they consider the next step. A hospital panel can assess candidacy from records long before anyone books a flight, and it is far better to learn you are not a candidate at that stage than after landing.

Seven questions worth asking any immunotherapy provider

1. Which family is this, precisely? Checkpoint inhibitor, engineered cell product, expanded autologous cells, vaccine? The word “immunotherapy” on its own tells you nothing.
2. What is the legal route? Marketing approval, registered clinical trial, or a special pathway with a hospital-held filing? Ask which, and ask to see it named.
3. What diagnosis is it licensed against, and do I have it? If the answer describes a state rather than a disease — ageing, low immunity, fatigue — the route does not exist under Chinese law.
4. Where are the cells manufactured, and what release testing do they pass? Viability, identity, sterility, endotoxin. A facility that will not answer this in writing is answering it.
5. Who decides candidacy, and can they decline me? A program with no meaningful exclusion criteria has no candidacy process. Who gets declined is the most informative question on this list.
6. What is the published evidence for this product in this indication? Not the class. Not a mouse. Named trials you can look up.
7. What happens afterwards, and who follows me up? Monitoring schedule, who reads it, what the escalation path is if something goes wrong once you are home.

Those seven work in any country, which is rather the point of them — the same logic applied across Switzerland, Thailand, Japan and the United States produces the same shortlist of things worth knowing before anyone takes your money.

Common questions

What is immune cell therapy?

Immune cell therapy means removing a patient's own immune cells, expanding or engineering them in a licensed cleanroom, and reinfusing them. It covers CAR-T and TCR-T (T cells given a new receptor), tumor-infiltrating lymphocytes, CIK and DC-CIK cells, and natural killer (NK) cells. It is one of five families sold under the word immunotherapy, alongside checkpoint inhibitors, cytokines, cancer vaccines, and bispecific engagers and oncolytic viruses. The families share a strategy and almost nothing else, including their legal status.

Is immunotherapy available in China to foreign patients?

Yes, but which kind depends entirely on the route. Checkpoint inhibitors are ordinary approved prescription medicines given in Chinese hospitals, and several CAR-T products have held national marketing approval since 2021 for relapsed or refractory B-cell lymphoma and multiple myeloma. Other adoptive cell therapies, including NK cells, have no marketing approval and run either inside registered clinical research or on a special pathway such as the Boao Lecheng pilot zone, where a hospital holds a filing for a specific product against specific disease indications.

Is CAR-T therapy approved in China?

Yes. Several chimeric antigen receptor T-cell products have won full national marketing approval in China since 2021, for relapsed or refractory B-cell lymphoma and later for multiple myeloma. They are manufactured from the patient's own T cells at licensed facilities and given in accredited hospitals with intensive-care capability, because the toxicity profile requires it. CAR-T is a treatment for specific blood cancers under haematology care and has nothing to do with wellness or longevity travel.

What is DC-CIK therapy, and is it still legal in China?

DC-CIK combines dendritic cells with cytokine-induced killer cells and was, for a decade, the cell therapy China was most associated with internationally. It sat on a restricted third-class medical technology catalogue from 2009; after that approval system was abolished in 2015 it was sold widely as a paid clinical service, and following the 2016 death of a young patient who bought it through a search advertisement, the health authority ruled that autologous immune cell therapy must be conducted as clinical research rather than sold as a service. Its published evidence, largely small unblinded single-centre trials, has never persuaded a regulator anywhere to approve it.

Can immunotherapy be used for anti-aging or to boost a healthy immune system?

Not lawfully in China. Under State Council Order No. 818, in force since 1 May 2026, a cell therapy is licensed against a named disease and never against age, so no immune cell product may be sold to a healthy person as rejuvenation or as an immune boost. Immune ageing is real and well described, but no immunotherapy is licensed to treat it anywhere in the world. The 2019 TRIIM study most often cited for thymic regeneration enrolled nine men with no control group and reported surrogate endpoints; it is a pilot, not a treatment.

What does immunotherapy cost in China?

There is no price list, and any site publishing one for licensed cell therapy is describing something other than a licensed program. Approved medicines such as checkpoint inhibitors are priced like medicines and many are on the national reimbursement list. Licensed cell-therapy programs are quoted by the hospital that would deliver them and confirmed in writing, because what a course costs depends on the diagnosis, the manufacturing run and the number of infusions. The four-day assessment retreat described on this site is offered from about $2,700 all in, against published Alpine longevity programmes at roughly $39,000 to $115,000 for a week.

What is the difference between NK cell therapy and CAR-T?

CAR-T takes the patient's T cells and engineers a synthetic receptor into them so they recognise one specific target, which is why it works dramatically in defined blood cancers and why it carries serious toxicities needing intensive-care backup. NK cell therapy expands the patient's own natural killer cells without engineering them; NK cells kill abnormal cells without prior sensitisation, which makes them broadly applicable in principle and hard to aim in practice. CAR-T is approved; NK therapy is not approved anywhere as a finished product, and in solid tumors the published evidence supports feasibility and tolerability rather than efficacy.

Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.